Last reviewed 2026-04-22 · How we verify

HDM1702

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

HDM1702 is a small molecule inhibitor targeting a specific molecular pathway in development for oncology indications.

At a glance

Generic name	HDM1702
Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

While specific mechanistic details for HDM1702 are limited in public literature, the drug is being developed by Hangzhou Zhongmei Huadong Pharmaceutical and is currently in phase 3 clinical trials. The exact molecular target and detailed mechanism of action require access to proprietary development data or clinical trial registries for complete characterization.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HDM1702 CI brief — competitive landscape report
HDM1702 updates RSS · CI watch RSS
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI